SequelSEC

VITASPRING BIOMEDICAL CO. LTD. VSBC

Services-Commercial Physical & Biological Research · CIK 0001697884 · Fiscal year ends 0131

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2026-01-31
Operating income
-$385.41K
Fiscal year ended 2026-01-31
Free cash flow
Unavailable
Fiscal year ended 2026-01-31

VITASPRING BIOMEDICAL CO. LTD. (VSBC) reported revenue of $0 and net income of -$415.37K for the fiscal year ended 2026-01-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from VITASPRING BIOMEDICAL CO. LTD.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Commercial Physical & Biological Research.

Income

VITASPRING BIOMEDICAL CO. LTD. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-01-312025-01-312024-01-312023-01-312022-01-312021-01-312020-01-312019-01-312018-01-312017-01-31
Revenue$0$0$0$0$5.61M$248.20KUnavailableUnavailable$16.23K$0
Cost of revenue$0$0$0$3.33M$3.55M$136.00KUnavailableUnavailable$4.89K$0
Gross profit$0$0$0-$3.33M$2.07M$112.20KUnavailableUnavailable$11.34K$0
Operating income-$385.41K-$679.91K-$1.12M-$4.18M$1.13M$425.38KUnavailableUnavailable-$6.37KUnavailable
Net income-$415.37K-$774.92K-$1.12M-$4.16M$909.56K$425.38KUnavailableUnavailable-$6.37K-$45
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 207.03Mshares 207.03Mshares 207.03Mshares 206.52Mshares 205.98Mshares 91.09MUnavailableUnavailableshares 2.29Mshares 49.32K
Pretax income-$385.41K-$679.91K-$1.12M-$4.17M$1.13M-$425.38KUnavailableUnavailableUnavailableUnavailable
Income tax expense$29.96K$95.01K$0-$5.38K$217.10K$0UnavailableUnavailableUnavailableUnavailable
Diluted EPS$0.00$0.00$-0.01$-0.02$0.00UnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrative$385.41K$679.91K$1.12M$844.84K$941.34K$537.58KUnavailableUnavailableUnavailableUnavailable
General & administrativeUnavailableUnavailableUnavailable$844.84K$941.34K$537.58KUnavailableUnavailable$17.71K$45
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

VITASPRING BIOMEDICAL CO. LTD. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-01-312025-01-312024-01-312023-01-312022-01-312021-01-312020-01-312019-01-312018-01-312017-01-31
Cash & equivalentsUnavailable$0$0Unavailable$107.21K$45.40KUnavailableUnavailable$5.21K$555
Total assets$14.68K$14.38K$137.34K$765.95K$3.60M$189.40KUnavailableUnavailable$1.87K$0
Current assets$10.53K$272$23.63K$437.08K$3.06M$189.40KUnavailableUnavailable$11.02K$4.56K
Total liabilities$4.45M$4.03M$3.49M$3.16M$2.03M$93.03KUnavailableUnavailable$12.89K$4.56K
Current liabilities$4.45M$4.03M$3.49M$3.07M$1.74M$93.03KUnavailableUnavailable$16.31K$1.60K
Total equity incl. NCI-$4.43M-$4.02M-$3.35M-$2.40M$1.58M$96.36KUnavailableUnavailable-$3.42K$2.96K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailable$0$0$144.00KUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailable$0$0$380.00K$2.95MUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$2.41M$2.41M$2.41M$2.41M$1.25MUnavailableUnavailableUnavailable$1.41K$0

Cash flow

VITASPRING BIOMEDICAL CO. LTD. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-01-312025-01-312024-01-312023-01-312022-01-312021-01-312020-01-312019-01-312018-01-312017-01-31
Operating cash flow-$2.69K-$14.68K-$34.92K-$77.56K-$269.63K-$42.13KUnavailableUnavailable$401-$4.04K
Capital expendituresUnavailableUnavailableUnavailable$0$73.00KUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailable$0-$73.00KUnavailableUnavailableUnavailable-$2.25K$0
Financing cash flow$4.50K$14.93K$5.28K$0$50.00K$87.53KUnavailableUnavailable$6.50K$4.60K
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$0$109.91K$164.86K$190.36K$167.17K$434.22KUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailable$9.96K$15.06KUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

VITASPRING BIOMEDICAL CO. LTD. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-01-312025-01-312024-01-312023-01-312022-01-312021-01-312020-01-312019-01-312018-01-312017-01-31
Free cash flowUnavailableUnavailableUnavailableUnavailable-$342.63KUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailable36.8%45.2%UnavailableUnavailable69.9%Unavailable
Operating marginUnavailableUnavailableUnavailableUnavailable20.1%171.4%UnavailableUnavailable-39.3%Unavailable
FCF marginUnavailableUnavailableUnavailableUnavailable-6.1%UnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailable3.0%174.9%UnavailableUnavailableUnavailableUnavailable
Current ratio0.00x0.00x0.01x0.14x1.76x2.04xUnavailableUnavailable0.68x2.85x
Revenue YoY growthUnavailableUnavailableUnavailable-100.0%2161.6%UnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailable16.2%171.4%UnavailableUnavailable-39.3%Unavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailable1.3%UnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable19.3%UnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open VSBC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-06-17View SEC filing
10-Q · Filed 2026-06-17View SEC filing
10-K · Filed 2026-06-17View SEC filing
10-Q · Filed 2026-06-17View SEC filing
10-Q · Filed 2026-06-15View SEC filing
10-K · Filed 2026-06-08View SEC filing

Companies in the same industry

ABSI BIAF BUDZ CBIH CRL FOXO IBAC INCY IQV ISPC MEDP MXCT

Reconciliation checks needing review

4 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2020-01-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2020-01-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2019-01-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2019-01-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.